Cell therapy weekly: first CAR-T cell therapy approved for relapsed or refractory MCL

Written by RegMedNet

Cell therapy weekly

This week: Kite Pharma (CA, USA) announces first FDA approval for CAR-T therapy to treat mantle cell lymphoma, CPI (Wilton, UK), MicrofluidX and the Cell and Gene Therapy Catapult (both London, UK) announce collaboration to scale up cell and gene therapy manufacture and researchers at the Wake Forest Institute for Regenerative Medicine (NC, USA) develop a novel cellular platform for the treatment of haemophilia A. The news highlights: FDA approves first CAR-T treatment for relapsed or refractory mantle cell lymphoma Collaborative project launched to scale up cell and gene therapy manufacture Novel cellular platform developed to treat patients with hemophilia...

To view the full article, please register now for access

It's completely free